As of July 1, Medicare Covers Wegovy for Weight Loss at $50 a Month. The Eligibility List Is Short. - 24/7 Wall St.

What the report says

24/7 Wall St. reports that a new Medicare demonstration program, called the Medicare GLP-1 Bridge, is scheduled to make certain weight-loss GLP-1 drugs available for a fixed $50 monthly copay beginning July 1, 2026. The program is described as temporary, nationwide and separate from standard Part D coverage, running through Dec. 31, 2027. Covered drugs listed in the report include Wegovy, Zepbound and Foundayo, but access depends on meeting detailed eligibility rules.

According to the report, beneficiaries must be enrolled in an eligible Medicare drug plan, and qualification depends on body mass index and specific medical conditions. A BMI of 35 or higher may qualify on its own; lower BMI thresholds require conditions such as certain kidney disease, uncontrolled hypertension, prediabetes, prior heart attack or stroke, symptomatic peripheral artery disease, or heart failure with preserved ejection fraction. A clinician must certify the qualifying information and submit prior authorization.

The article emphasizes that several groups many patients might expect to be included are instead excluded from the $50 bridge. People prescribed GLP-1 drugs for type 2 diabetes, moderate-to-severe obstructive sleep apnea, or qualifying liver disease must seek coverage through their Part D plan rather than the bridge. The report also says the $50 payment will not count toward Part D deductibles, the annual out-of-pocket cap, Extra Help reductions or Medicare’s prescription payment plan.

The development matters because GLP-1 drugs can carry high retail prices, and a fixed monthly cost could substantially reduce expenses for beneficiaries who qualify. However, 24/7 Wall St. frames the program as limited rather than broad Medicare coverage for weight-loss medications.